Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Share-based Compensation (2017 - 2025)

Puma Biotechnology's Share-based Compensation history spans 9 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 7.71% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $6.9 million, down 15.78%, while the annual FY2025 figure was $6.9 million, 15.78% down from the prior year.
  • Share-based Compensation reached $1.6 million in Q4 2025 per PBYI's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $18.2 million in Q2 2021 to a low of -$14.8 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $2.5 million, with a median of $2.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: tumbled 256.03% in 2021, then surged 117.78% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at -$14.8 million in 2021, then soared by 117.78% to $2.6 million in 2022, then decreased by 7.46% to $2.4 million in 2023, then decreased by 27.96% to $1.8 million in 2024, then dropped by 7.71% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Share-based Compensation are $1.6 million (Q4 2025), $1.7 million (Q3 2025), and $1.6 million (Q2 2025).